why choose us

First received: October 13, 2022

Clinical Trial: Evaluating a Pharmacogenetic Testing Panel in Patients Suspected to be at Increased Risk for Pharmacogenetics-related AEs While Receiving Fluoropyrimidine or Irinotecan Therapy

Study Status: Completed

Recruit Status: RECRUITING

Condition: Cancer

Study Type: INTERVENTIONAL


Official Title: Evaluating the Uptake and Impact of a Pharmacogenetic Testing Panel in Patients Suspected to be at Increased Risk for Pharmacogenetics-related AEs While Receiving Fluoropyrimidine or Irinotecan Therap

Brief Summary: This study will be evaluating patients suspected to carry DPYD or UGT1A1 variants based off of Michigan Genomics Initiative (MGI) results.Standard of care treatment will be initiated with either Fluoropyrimidine or Irinotecan therapy.Retrospective collection of treatment related AEs and SAEs, dose delays, dose reductions, and treatment discontinuations will be completed.

Read more